Dosing Enhancements May Improve Treatment Experience for Patients Receiving AVONEX® (interferon beta-1a) for Multiple Sclerosis WESTON, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) ...
AVONEX PEN (interferon beta-1a) 30mcg/0.5mL solution for injection by Biogen Idec The Avonex Pen (interferon beta-1a 30mcg/0.5mL solution for injection), the first IM autoinjector for chronic use in ...
Biogen Idec BIIB today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX dose titration, or gradual dose escalation, on flu-like ...
The FINANCIAL — WESTON, Mass., Jun 06, 2011 — Biogen Idec today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX(R) (interferon ...
AVONEX PEN, the first intramuscular (IM) autoinjector approved for MS, incorporates a smaller needle and easier administration to help patients reduce anxiety about AVONEX self-injection. A new dose ...
WESTON, Mass. — The Food and Drug Administration has approved two separate dosing innovations for multiple sclerosis patients that are being treated with a Biogen Idec drug. Biogen Idec said the FDA ...
AVONEX PEN (interferon beta-1a) 30mcg/0.5mL solution for injection by Biogen Idec Biogen Idec has received approval from the FDA for Avonex Pen (30mcg/0.5mL solution for injection) for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results